UPDATE: KeyBanc Upgrades BioMed Realty Trust to Buy on Lease-Up and Accretive Acquisitions
Posted on February 14, 2013 at 11:14 AM EST
KeyBanc upgraded BioMed Realty Trust (NYSE: BMR ) from Hold to Buy and announced a $24.00 price target. KeyBanc commented, "Following strong execution on the leasing front, a pipeline of accretive investment activity and a reloading of the balance sheet, we are upgrading shares of BioMed Realty Trust (BMR-NYSE) to